Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03544827 · ClinicalTrials.gov registry record · Phase 4
The Effects of Low Dose Atropine on Choroidal Thickness
A Phase 4 study, sponsored by State University of New York College of Optometry.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT03544827 is a Phase 4 study that has completed, run by State University of New York College of Optometry. The registered enrollment target is 36 participants.
The verdict
NCT03544827, a Phase 4 study, has completed, sponsored by State University of New York College of Optometry.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Atropine eye drops are considered to be an effective form of myopia control in human eyes. However, the mechanism by which it exerts it effects are not fully understood. Thickening of the choroid subsequent to atropine administration may play an important role in the mechanisms by which atropine induces myopia control. Literature also notes that choroidal thickness undergoes diurnal variations, which is a variable that will be controlled in this study in order to examine atropine's effects on different baseline choroidal thicknesses. The purpose of the proposed study is to characterize better the influence of atropine on choroid thickness. The study aims are to: 1. Determine the effect of low dose concentration of topical atropine (0.1% and 0.01%) on choroid thickness 2. Determine the effect of topical atropine on choroid thickness in relationship to baseline thickness throughout the day and after one week of daily instillation Hypothesis: Atropine's effect on choroidal thickness will be dependent on the subject's baseline thickness measurements, at a designated time of the day when the choroid is at its thinnest.
Interventions
- DRUG Atropine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2019-02-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03544827
The ClinicalTrials.gov registry entry for NCT03544827 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York College of Optometry, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atropine is the first listed.
NCT03544827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03544827 about?
NCT03544827 is a clinical study titled "The Effects of Low Dose Atropine on Choroidal Thickness". Atropine eye drops are considered to be an effective form of myopia control in human eyes. However, the mechanism by which it exerts it effects are not fully understood. Thickening of the choroid subsequent to atropine administration may play an important role in the mechanisms by which atropine ind...
What is the current status of trial NCT03544827?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2018-05-21. Estimated completion is 2019-02-08.
What interventions are being tested in trial NCT03544827?
The interventions under investigation include: Atropine (DRUG).
Who is sponsoring clinical trial NCT03544827?
This trial is sponsored by State University of New York College of Optometry, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.